Verastem launches three Phase 2 trials, discloses going concern as cash runway tightens

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~2 min read

Key Changes

• high

  Company disclosed substantial doubt about ability to continue as going concern, triggered by initiating three Phase 2 trials for VS-7375 after filing its 10-K. Increased R&D costs exceed available cash runway within 12 months without additional financing.

  MD&A: Going Concern; Risk Factors verify on EDGAR →
• high

  First full quarter of AVMAPKI FAKZYNJA CO-PACK sales generated $18.7M revenue with $2.8M cost of sales (15% gross margin), following May 2025 U.S. launch. Margin will improve as pre-approval inventory depletes.

  MD&A: Product Revenue verify on EDGAR →
• high

  Initiated TARGET-D 201, 202, and 203 trials evaluating VS-7375 at 900mg daily in second-line pancreatic cancer, NSCLC, and colorectal cancer. Dose escalation continues to 1200mg with no dose-limiting toxicities reported across 23 patients.

  MD&A: VS-7375 Clinical Program verify on EDGAR →